IRIS
SANTORO, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.805
AS - Asia 22.933
EU - Europa 8.376
SA - Sud America 4.519
AF - Africa 1.219
Continente sconosciuto - Info sul continente non disponibili 793
OC - Oceania 38
AN - Antartide 1
Totale 79.684
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 40.808
SG - Singapore 14.242
BR - Brasile 3.706
CN - Cina 3.396
VN - Vietnam 2.365
IT - Italia 2.357
FI - Finlandia 1.407
IE - Irlanda 1.126
NG - Nigeria 809
DE - Germania 732
HK - Hong Kong 720
FR - Francia 660
CA - Canada 612
GB - Regno Unito 458
IN - India 436
NL - Olanda 375
SE - Svezia 317
AR - Argentina 298
TR - Turchia 282
BD - Bangladesh 234
IQ - Iraq 194
RU - Federazione Russa 183
MX - Messico 178
IL - Israele 146
EC - Ecuador 140
ID - Indonesia 121
ZA - Sudafrica 115
JP - Giappone 114
CO - Colombia 106
PL - Polonia 105
BE - Belgio 100
UA - Ucraina 99
ES - Italia 92
PK - Pakistan 87
CL - Cile 79
MA - Marocco 78
UZ - Uzbekistan 66
VE - Venezuela 64
SA - Arabia Saudita 54
PY - Paraguay 53
MY - Malesia 48
PH - Filippine 46
JO - Giordania 40
AE - Emirati Arabi Uniti 38
EG - Egitto 36
TN - Tunisia 36
RO - Romania 35
CZ - Repubblica Ceca 34
IR - Iran 34
LT - Lituania 34
DZ - Algeria 33
JM - Giamaica 33
AT - Austria 32
AU - Australia 32
KE - Kenya 32
NP - Nepal 32
KR - Corea 31
UY - Uruguay 31
CR - Costa Rica 30
PE - Perù 26
CH - Svizzera 25
DO - Repubblica Dominicana 24
KZ - Kazakistan 24
HN - Honduras 23
OM - Oman 23
AZ - Azerbaigian 22
A2 - ???statistics.table.value.countryCode.A2??? 21
BG - Bulgaria 21
EU - Europa 21
TH - Thailandia 20
TT - Trinidad e Tobago 20
HU - Ungheria 19
ET - Etiopia 18
PT - Portogallo 18
GR - Grecia 16
GT - Guatemala 16
LB - Libano 15
NO - Norvegia 14
SN - Senegal 14
BY - Bielorussia 13
NI - Nicaragua 13
TW - Taiwan 13
AL - Albania 12
PA - Panama 12
RS - Serbia 12
AM - Armenia 11
BO - Bolivia 11
KG - Kirghizistan 11
MD - Moldavia 10
SI - Slovenia 10
SV - El Salvador 10
SY - Repubblica araba siriana 10
BH - Bahrain 9
DK - Danimarca 9
HR - Croazia 9
KW - Kuwait 9
LV - Lettonia 9
PS - Palestinian Territory 9
BA - Bosnia-Erzegovina 8
CG - Congo 8
Totale 78.799
Salva come PNG Salva come JPEG
Città #
Singapore 6.566
Wilmington 5.558
Chandler 4.575
Ashburn 2.417
The Dalles 2.233
San Mateo 2.024
Dallas 1.828
Ann Arbor 1.546
Shanghai 1.477
Helsinki 1.397
San Jose 1.387
Council Bluffs 1.260
Dublin 1.116
Milan 1.006
Princeton 959
Leawood 943
Lawrence 911
New York 893
Boardman 839
Benin City 804
Ho Chi Minh City 794
Beijing 768
Hong Kong 669
Hanoi 576
Paris 518
Woodbridge 515
Fairfield 513
Santa Clara 451
Los Angeles 449
Rome 346
Toronto 343
Amsterdam 329
São Paulo 308
Buffalo 253
Seattle 252
Phoenix 251
London 229
Columbus 180
Kocaeli 180
San Diego 178
Rio de Janeiro 132
Da Nang 122
Norwalk 122
Haiphong 105
Orem 98
Chicago 96
Belo Horizonte 93
Brussels 88
Brooklyn 86
Warsaw 85
Charlotte 83
Tokyo 82
Montreal 81
Falkenstein 79
Pune 78
Naples 75
Falls Church 74
Figino 74
Baghdad 67
Chennai 65
Brasília 63
Curitiba 63
Mexico City 63
Tashkent 63
Houston 62
Redwood City 60
Porto Alegre 59
Munich 57
Johannesburg 56
Guayaquil 55
Philadelphia 55
Moscow 54
Atlanta 53
Dhaka 50
Monmouth Junction 50
San Francisco 50
Manchester 49
Campinas 48
Boston 46
Frankfurt am Main 46
Hải Dương 46
Miami 46
Biên Hòa 43
Las Vegas 43
Mumbai 40
Abbiategrasso 39
Redmond 39
Salvador 39
Turin 38
Erbil 37
Amman 36
Pasadena 36
Stockholm 36
Denver 35
Goiânia 35
Istanbul 34
Queens 34
Cincinnati 33
Hillsboro 33
Guarulhos 32
Totale 51.482
Salva come PNG Salva come JPEG
Nome #
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 180
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 176
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) 175
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 164
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment 162
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogenic stem call transplantation from a HLA identical sibling 161
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 160
A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma 158
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 156
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 152
A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial 151
Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature 148
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 147
A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS 146
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 145
Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience 145
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases 144
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study 139
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 139
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 138
A new human cell line, PDSS-26, from poorly differentiated synovial sarcoma, with unique chromosomal anomalies 138
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 137
A circulating miRNA signature to implement diagnostic imaging analysis in young early-stage breast cancer patients 137
BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors 136
Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial 136
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 134
Tivantinib for hepatocellular carcinoma 133
A phase I clinical and pharmacokinetic study evaluating vinflumine in combination with epirubicin as first-line treatment in metastatic breast cancer 132
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 132
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 131
A Phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small cell lung cancer. 130
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 130
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 129
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 128
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA 126
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid 126
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach 126
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers 126
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study 126
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 125
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 125
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 125
Alternating drug combinations in the treatment of advanced Hodgkin's disease. 124
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 124
Biomarkers in Hepatocellular Carcinoma-Letter 123
Biological characteristics and long-term outcomes in node-negative breast cancer 123
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies 122
Treatment of malignant pleural mesothelioma: current status and future directions 122
Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial 121
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. 121
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 121
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 120
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer 119
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 118
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up 118
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 117
COVID-19 and liver cancer clinical trials: not everything is lost 115
COMBINED-MODALITY TREATMENT FOR PRIMARY GASTROINTESTINAL NON-HODGKINS-LYMPHOMA - THE MILAN CANCER INSTITUTE EXPERIENCE 115
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 115
Survival outcome and prognostic factors after pulmonary metastasectomy in sarcoma patients 114
DEXAMETHASONE, GRANISETRON, OR BOTH FOR THE PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY FOR CANCER 114
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 114
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 113
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant 113
. The level of HER2/neu amplification may have a correlation with some relevant histopathologcal features of early stage breast cancer 113
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 113
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 113
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 112
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 112
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma 112
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 112
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 112
Superiority of CHOI vs RECIST criteria in evaluating outcome of advanced soft tissue sarcoma (STS) patients treated with sorafenib 112
Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation 111
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome 111
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. 110
Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. 110
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 110
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 109
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 108
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 108
Advances in the biology of malignant pleural mesothelioma 108
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 107
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 107
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 107
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 107
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 106
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. 106
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography 106
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 106
A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC 106
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 105
Anatomic location of breast cancer micrometastasis in sentinel lymph node predicts axillary status 105
Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction 105
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). 105
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 105
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma 104
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 104
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. 104
Percutaneous Vertebral Augmentation in Metastatic Disease: State of the Art 104
Totale 12.455
Salva come PNG Salva come JPEG
Categoria #
all - tutte 529.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 529.568
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.665 0 72 123 1.100 86 83 202 732 426 556 1.050 235
2022/202312.810 2.013 413 1.232 1.406 1.154 1.075 32 1.083 2.224 1.120 906 152
2023/20246.764 616 732 1.517 242 195 721 323 368 87 140 696 1.127
2024/202510.261 245 192 54 176 234 1.187 534 1.207 1.458 2.604 1.158 1.212
2025/202629.275 4.175 1.970 1.856 2.948 755 1.187 8.085 1.668 1.676 1.707 1.130 2.118
2026/20275.180 2.707 2.473 0 0 0 0 0 0 0 0 0 0
Totale 79.684